Pathogenetic targets of chronic migraine: rationale for the use of botulinum toxin type A and anti-CGRP therapy
Clinical review for general practice · 25.05.2026 · 7 (3) · 32-37
DOI: 10.47407/kr2026.7.3.00790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 25.05.2026. Verfasst von Polina S Krivonozhkina und 3 weiteren Autor:innen.
Abstract (Originalsprache)
This article presents a literature review examining the pathogenetic rationale for current chronic migraine treatments using botulinum toxin type A and monoclonal antibodies to calcitonin gene-related peptide (CGRP). The 2024 revision of the Migraine Clinical Guidelines, as well as literature from databases such as PubMed, eLibrary, and CyberLeninka, were used for this review. The high prevalence of migraine patients, increased attack frequency, increased headache intensity, and chronic hemicranialgia significantly reduce their quality of life, limiting their professional, social, and family activities. Current pathogenetically based migraine therapy using botulinum toxin type A and monoclonal antibodies to CGRP has demonstrated high efficacy and safety. The mechanisms of action of these drugs are continuing to be studied to assess not only the early but also the long-term consequences of their use. The question of a reasonable combination of these two methods in the same patient with refractory migraine remains relevant, which requires further observation to develop optimal regimens for the relief of chronic algic paroxysms. Keywords: headache, migraine, botulinum toxin, monoclonal antibodies to calcitonin gene-related peptide.
Zitieren
APA
Krivonozhkina, P. S., Miroshnikova, V. V., Poplavskaya, A. A., & Shorina, M. N. (2026). Pathogenetic targets of chronic migraine: rationale for the use of botulinum toxin type A and anti-CGRP therapy. Clinical review for general practice, 7(3), 32-37. https://doi.org/10.47407/kr2026.7.3.00790
Vancouver
Krivonozhkina PS, Miroshnikova VV, Poplavskaya AA, Shorina MN. Pathogenetic targets of chronic migraine: rationale for the use of botulinum toxin type A and anti-CGRP therapy. Clinical review for general practice. 2026;7(3):32-37. doi:10.47407/kr2026.7.3.00790
BibTeX
@article{Krivonozhkina2026,
author = {Krivonozhkina, Polina S and Miroshnikova, Valentina V and Poplavskaya, Anastasia A and Shorina, Maya N},
title = {Pathogenetic targets of chronic migraine: rationale for the use of botulinum toxin type A and anti-CGRP therapy},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {3},
pages = {32--37},
doi = {10.47407/kr2026.7.3.00790}
}
EUVIMED